About: Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background: Defects in the p53 gene predispose B CLL patients for an inferior outcome, particularly a resistance to treatment by conventional chemotherapeutics. Very little data exist, however, about the efficacy of monoclonal antibody rituximab on B CLL cells bearing p53 abnormalities. One reason for that might be a methodological: rituximab alone does not have virtually any effect on the viability of B CLL cells when cultivated in vitro, unless an active human plasma is added. After that, however, the cells are quickly lysed by complement, what is a process independent on p53. Aims: We used an in vitro system (not containing the active human plasma) to monitor a rituximab activity on B CLL cells with p53 inactivation in relation to subsequently used nucleoside analog fludarabine, which demonstrably acts through the p53 in B CLL cells. Background: Defects in the p53 gene predispose B CLL patients for an inferior outcome, particularly a resistance to treatment by conventional chemotherapeutics. Very little data exist, however, about the efficacy of monoclonal antibody rituximab on B CLL cells bearing p53 abnormalities. One reason for that might be a methodological: rituximab alone does not have virtually any effect on the viability of B CLL cells when cultivated in vitro, unless an active human plasma is added. After that, however, the cells are quickly lysed by complement, what is a process independent on p53. Aims: We used an in vitro system (not containing the active human plasma) to monitor a rituximab activity on B CLL cells with p53 inactivation in relation to subsequently used nucleoside analog fludarabine, which demonstrably acts through the p53 in B CLL cells. (en)
Title	Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine (en)
skos:prefLabel	Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine Rituximab Senzitizes B-CLL Cells with Inactived p53 to fludarabine (en)
skos:notation	RIV/00216224:14310/06:00019160!RIV10-MZ0-14310___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(LC06024), P(NR8445)
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Pospíšil, Zdeněk Chumchalová, Jitka Pospíšilová, Šárka Brychtová, Yvona Kuglík, Petr Doubek, Michael Mayer, Jiří Šmardová, Jana Trbušek, Martin Čejková, Soňa
http://linked.open.../riv/druhVysledku	O - Ostatní výsledky nezařaditelné do žádného z výše uvedených druhů výsledku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Přírodovědecká fakulta
http://linked.open...dnocenehoVysledku	497634
http://linked.open...ai/riv/idVysledku	RIV/00216224:14310/06:00019160
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	B-CLL p53 rituximab fludarabine in vitro (en)
http://linked.open.../riv/klicoveSlovo	B-CLL p53 rituximab fludarabine in vitro
http://linked.open...ontrolniKodProRIV	[98F2AEE2B8A1]
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	10 (xsd:int)
http://linked.open...cetTvurcuVysledku	10 (xsd:int)
http://linked.open...vavai/riv/projekt	Jaroslav Hájek Center for Theoretical and Applied Statistics In vitro sensitivity/resistance of CLL cells with inactivated p53 on modern therapy
http://linked.open...UplatneniVysledku	2006
http://linked.open...iv/tvurceVysledku	Brychtová, Yvona Doubek, Michael Kuglík, Petr Mayer, Jiří Pospíšilová, Šárka Pospíšil, Zdeněk Trbušek, Martin Šmardová, Jana Čejková, Soňa Chumchalová, Jitka
http://localhost/t...ganizacniJednotka	14310

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software